A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy.
Humans
Adenine
/ analogs & derivatives
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Piperidines
/ therapeutic use
Female
SARS-CoV-2
COVID-19
/ virology
Virus Shedding
CD8-Positive T-Lymphocytes
/ immunology
Pyrimidines
/ therapeutic use
CD4-Positive T-Lymphocytes
/ immunology
Aged
Pyrazoles
/ therapeutic use
Middle Aged
COVID-19
Chronic lymphocytic leukemia
Immunosuppressive treatment
Prolonged viral shedding
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
10
12
2023
accepted:
22
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
1
9
2024
Statut:
epublish
Résumé
Patients on B cell immunosuppressive treatments have been shown to have persistent infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this report, a woman treated with ibrutinib for chronic lymphocytic leukemia experienced more than 40 days of coronavirus disease 2019 (COVID-19) infection. Unexpectedly, her peripheral blood experiments showed a normal SARS-CoV-2-specific antibody level and a relatively elevated percentage of CD19 + B cells, while an obvious decrease in the percentages of NK cells, CD4 + T cells and CD8 + T cells. Further SARS-CoV-2-specific T cell analysis in this patient indicated a significant decrease in the percentage of SARS-CoV-2-specific IFN-γ, TNF-α or IL-2 producing CD4 + T or CD8 + T cells. Most notably, ten days after the cease of ibrutinib, the PCR for SARS-CoV-2 turned negative and the reduced proportions of peripheral CD4 + T cells and CD8 + T cells recovered. Our research predicted that the depleted B-cell function therapies may play considerable role in the development of long COVID-19 and the abnormal T-cell subset distribution might be the underlying mechanism.
Identifiants
pubmed: 39218877
doi: 10.1186/s12879-024-09794-z
pii: 10.1186/s12879-024-09794-z
doi:
Substances chimiques
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Piperidines
0
Pyrimidines
0
Pyrazoles
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
895Informations de copyright
© 2024. The Author(s).
Références
Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–94.
doi: 10.1001/jama.2020.3204
pubmed: 32125362
pmcid: 7054855
Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020;383(26):2586–8.
doi: 10.1056/NEJMc2031670
pubmed: 33259154
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.
doi: 10.1016/S1470-2045(20)30096-6
pubmed: 32066541
pmcid: 7159000
Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020;95(8):E199–203.
doi: 10.1002/ajh.25851
pubmed: 32356356
pmcid: 7267481
Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014;10(6):957–67.
doi: 10.2217/fon.14.51
pubmed: 24941982
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.
doi: 10.1056/NEJMoa1501548
pubmed: 25853747
Kim ES, Dhillon S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015;75(7):769–76.
doi: 10.1007/s40265-015-0380-3
pubmed: 25802231
Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR. BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte). Clin Cancer Res. 2020;26(14):3514–6.
doi: 10.1158/1078-0432.CCR-20-1427
pubmed: 32345646
pmcid: 7367762
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–43.
doi: 10.1182/blood.2020006965
pubmed: 32688395
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354–63.
doi: 10.1038/s41375-020-0959-x
pubmed: 32647324
pmcid: 7347048
Lin AY, Cuttica MJ, Ison MG, Gordon LI. Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. EJHaem. 2020;1(2):596–600.
doi: 10.1002/jha2.98
pubmed: 33043320
pmcid: 7537222
Fiorcari S, Atene CG, Maffei R, Debbia G, Potenza L, Luppi M, et al. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. Haematologica. 2021;106(8):2265–8.
doi: 10.3324/haematol.2020.277392
pubmed: 33691383
pmcid: 8327720
Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SEM, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–9.
doi: 10.1182/blood-2015-04-639203
pubmed: 26337493
pmcid: 4635117
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
doi: 10.1056/NEJMoa1215637
pubmed: 23782158
pmcid: 3772525
Wei D, Chen Y, Yu X, Lai YD, Xu W, Ji P, et al. Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination. Emerging microbes & infections. 2022;11(1):2474–84.
doi: 10.1080/22221751.2022.2130101
Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, et al. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Arch Chest Dis. 2021;91(4).
Nakamura S, Kanemasa Y, Atsuta Y, Fujiwara S, Tanaka M, Fukushima K, et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo. Japan Int J Clin Oncol. 2021;26(3):485–93.
doi: 10.1007/s10147-020-01837-0
pubmed: 33225396
Hao S, Lian J, Lu Y, Jia H, Hu J, Yu G, et al. Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study. J Infect Dis. 2020;222(3):367–71.
doi: 10.1093/infdis/jiaa311
pubmed: 32474608
Bacova B, Kohutova Z, Zubata I, Gaherova L, Kucera P, Heizer T, et al. Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. Clin Exp Med. 2023;23(2):371–9.
doi: 10.1007/s10238-022-00809-0
pubmed: 35352210
Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257–1275.e1258.
doi: 10.1016/j.immuni.2021.05.010
pubmed: 34051148
pmcid: 8125900
Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, et al. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci Immunol. 2021;6(62):eabg5021.
Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis. 2021;223(1):23–7.
doi: 10.1093/infdis/jiaa666
pubmed: 33089317
Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discov. 2022;12(1):62–73.
doi: 10.1158/2159-8290.CD-21-1033
pubmed: 34753749
Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, Fernández-Román IM, López-Barba J, de la Cruz-Merino L, et al. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. Front Immunol. 2022;13: 860891.
doi: 10.3389/fimmu.2022.860891
pubmed: 35493500
pmcid: 9046988